Decreasing R&D/sales percentage with severe polarization among companies

Published: 2018-04-04 13:11:34

Updated: 2018-04-04 13:11:34

The listed pharmaceutical companies’ percentage of R&D expenses to sales is decreasing while the polarization among companies in the category is getting severe.

Yakup Shinmoon(www.yakup.com) analyzed 2018 business reports that 65 listed pharmaceutical companies made, and the analysis result showed these pharmaceutical companies reportedly spent 7.95% of sales into R&D on average. (holding and ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.